Coherus Biosciences (NASDAQ:CHRS) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.
CHRS has been the topic of a number of other reports. ValuEngine downgraded Coherus Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday. Citigroup reiterated a “buy” rating and issued a $23.00 price target on shares of Coherus Biosciences in a report on Tuesday, November 7th. Finally, Zacks Investment Research upgraded Coherus Biosciences from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Wednesday, January 3rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Coherus Biosciences has a consensus rating of “Buy” and an average price target of $29.67.
Shares of Coherus Biosciences (CHRS) traded down $0.10 during trading hours on Friday, hitting $9.95. The stock had a trading volume of 428,747 shares, compared to its average volume of 732,412. Coherus Biosciences has a twelve month low of $8.05 and a twelve month high of $27.45. The stock has a market cap of $570.82, a P/E ratio of -1.84 and a beta of 3.81. The company has a debt-to-equity ratio of 1.84, a current ratio of 5.46 and a quick ratio of 5.46.
Institutional investors have recently bought and sold shares of the company. Temasek Holdings Private Ltd acquired a new stake in shares of Coherus Biosciences in the 3rd quarter worth $87,524,000. New York State Common Retirement Fund boosted its position in shares of Coherus Biosciences by 32.1% in the 2nd quarter. New York State Common Retirement Fund now owns 43,600 shares of the biotechnology company’s stock worth $626,000 after purchasing an additional 10,599 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of Coherus Biosciences in the 2nd quarter worth $602,000. Fox Run Management L.L.C. acquired a new stake in shares of Coherus Biosciences in the 4th quarter worth $228,000. Finally, Northern Trust Corp boosted its position in shares of Coherus Biosciences by 13.8% in the 2nd quarter. Northern Trust Corp now owns 464,056 shares of the biotechnology company’s stock worth $6,660,000 after purchasing an additional 56,122 shares in the last quarter. 81.48% of the stock is owned by hedge funds and other institutional investors.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.